There are 2789 resources available
826O - Copanlisib plus rituximab vs placebo plus rituximab in patients (pts) with relapsed marginal zone lymphoma (MZL) treated in the phase III CHRONOS-3 trial
Presenter: Muhit Özcan
Session: Proffered Paper session - Haematological malignancies
Resources:
Abstract
Slides
Webcast
833O - A phase Ib study result of HMPL-689, a PI3Kδ inhibitor, in Chinese patients with relapsed/refractory lymphoma
Presenter: Junning Cao
Session: Proffered Paper session - Haematological malignancies
Resources:
Abstract
Slides
Webcast
LBA47 - Activity of OSE-2101 in HLA-A2+ non-small cell lung cancer (NSCLC) patients after failure to immune checkpoint inhibitors (IO): Final results of phase III Atalante-1 randomised trial
Presenter: Benjamin Besse
Session: Proffered Paper session - NSCLC, metastatic 2
Resources:
Abstract
Slides
Webcast
1281O - Atezolizumab (atezo) vs platinum-based chemo in blood-based tumour mutational burden-positive (bTMB+) patients (pts) with first-line (1L) advanced/metastatic (m)NSCLC: Results of the Blood First Assay Screening Trial (BFAST) phase III cohort C
Presenter: Rafal Dziadziuszko
Session: Proffered Paper session - NSCLC, metastatic 2
Resources:
Abstract
Slides
Webcast
LBA48 - DUBLIN-3 (BPI-2358-103): A global phase (Ph) III trial with the plinabulin/docetaxel (Plin/Doc) combination vs. Doc in 2nd/3rd Line NSCLC patients (pts) with EGFR-wild type (wt) progressing on a prior platinum-based regimen
Presenter: Trevor Feinstein
Session: Proffered Paper session - NSCLC, metastatic 2
Resources:
Abstract
Slides
Webcast
1191O - MRTX-500: Phase II trial of sitravatinib (sitra) + nivolumab (nivo) in patients (pts) with non-squamous (NSQ) non-small cell lung cancer (NSCLC) progressing on or after prior checkpoint inhibitor (CPI) therapy
Presenter: Ticiana Leal
Session: Proffered Paper session - NSCLC, metastatic 2
Resources:
Abstract
Slides
Webcast
1502O - OncoYoung program: A multidisciplinary program for young cancer patients
Presenter: Irit Ben-Aharon
Session: Proffered Paper session - Public policy
Resources:
Abstract
Slides
Webcast
1503O - Clinical and scientific impact of National Cancer Institute: Sponsored clinical trial network group treatment trials
Presenter: Joseph Unger
Session: Proffered Paper session - Public policy
Resources:
Abstract
Slides
Webcast
1504O - Anti-cancer drug price regulation in India: Financial implications and annual savings to patients
Presenter: Krishnamani Kalpathi
Session: Proffered Paper session - Public policy
Resources:
Abstract
Slides
Webcast
Q&A and live discussion
Presenter: Olga Husson
Session: Proffered Paper session - Public policy
Resources:
Slides
Webcast